Claire F. Friedman

Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study

Milind Javle, Mitesh J. Borad, Nilofer S. Azad et al. · The Lancet Oncology · 2021 · 406 citations

Medicine, Oncology, Pharmacology +13

Ovarian cancer mutational processes drive site-specific immune evasion

Ignacio Vázquez-Garćıa, Florian Uhlitz, Nicholas Ceglia et al. · Nature · 2022 · 307 citations · Full text

Medicine, Immunology, Oncology +17

Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer

Tara E. Soumerai, Mark T.A. Donoghue, Chaitanya Bandlamudi et al. · Clinical Cancer Research · 2018 · 164 citations

Medicine, Oncology, Pathology +17

Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma

Alexander N. Shoushtari, Claire F. Friedman, Pedram Navid-Azarbaijani et al. · JAMA Oncology · 2017 · 163 citations

Medicine, Oncology, Pharmacotherapy +17

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma

Samuel Rosner, Erica Kwong, Alexander N. Shoushtari et al. · Cancer Medicine · 2018 · 127 citations · Full text

Life Sciences, Immunology, Oncology +17